image credit: Adobe Stock

Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

September 27, 2023


Riding high from sales of an mpox vaccine, Bavarian Nordic began 2023 with one major goal in mind: becoming one of the largest pure-play vaccine manufacturers in the world.

While the Danish biotechnology company has worked on vaccines since its founding in the early ‘90s, it has largely relied on government contracts, including for its smallpox and mpox shot Jynneos, to stay afloat. Although the approach was successful — the company sold almost 5.5 million doses of its mpox vaccine to the U.S. government during the surge of cases last summer — the business model is “lumpy,” CEO Paul Chaplin said.

Read More on Biopharma Dive